官方服务：
资源简介：
Discovery of anti-virulence drugs against Pseudomonas aeruginosa infections
应用场景：
创建时间：
2023-12-31
相关数据集
Exposure of cystic fibrosis bronchial epithelial cells (CFBE 41 o-) to Pseudomonas aeruginosa (PA01) biofilms. Homo sapiens
In the clinical setting, mutations in the CFTR gene enhance the inflammatory response to P. aeruginosa (PA01) infection, but measurements of the inflammatory response to pathogen stimulation by isolat
NIAID Data Ecosystem90
Pathological, flow cytometry, cytokine, and RT-qPCR results at different time points before and after Pseudomonas aeruginosa infection.
Pathological, flow cytometry, cytokine, and RT-qPCR results at different time points before and after Pseudomonas aeruginosa infection.
Figshare2024-11-17 更新10
Characterisation of Pseudomonas aeruginosa from lung explant of a patient with primary ciliary dyskinesia
Background/Aims Primary ciliary dyskinesia (PCD) is a rare inherited disease characterized by abnormal ciliary function, leading to compromised mucociliary clearance and persistent bacterial infection
NIAID Data Ecosystem00
Characteristics of the study group.
Abbreviations: FEV1% Forced experatory volume in one second expressed as percentage of predicted, P.aeruginosa; Pseudomonas aeruginosa.
NIAID Data Ecosystem90
Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections or Lower respiratory tract Infections Caused by extensively drug-resistance or pan drug-resistance (XDR/PDR) Pseudomonas aeruginosa
To evaluate the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) - causing extensively drug-res
NIAID Data Ecosystem00
